![Morten Kjærgaard Jakobsen](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Morten Kjærgaard Jakobsen
Director/Board Member at Nuevolution A/S
Network origin in Morten Kjærgaard Jakobsen first degree
Entity | Entity type | Industry | |
---|---|---|---|
Nuevolution A/S
![]() Nuevolution A/S Miscellaneous Commercial ServicesCommercial Services Nuevolution A/S engages in research and experimental development on biotechnology. It produces and commercializes technologies for the manufacture of substances for use in the pharmaceutical industry by screening non-biological polymers and low-molecular substances. The company was founded on May 8, 2001 and is headquartered in Copenhagen, Denmark.
4
| Subsidiary | Miscellaneous Commercial Services | 4 |
Chart of Companies connected to the second degree
Multi-company connection
Companies connected to Morten Kjærgaard Jakobsen via their personal network
Company | Sector | Related people | Main position |
---|---|---|---|
University of Aarhus | College/University | Doctorate Degree | |
NTG NORDIC TRANSPORT GROUP A/S | Trucking | Director/Board Member | |
Atz Holding ApS | Chief Executive Officer | ||
University of Southern Denmark | College/University | Graduate Degree | |
Evolva SA
![]() Evolva SA Miscellaneous Commercial ServicesCommercial Services Evolva SA is a Swiss-headquartered, international pharmaceutical biotech company focused on the discovery and development of drugs based on its distinctive and proprietary genetic chemistry platform. The company was founded in Switzerland in 2004 based on US/Danish technology. Evolva is headquartered in Allschwil/Basel with operations in Denmark, India and the USA. The Company has raised CHF 38.2 million of equity to date and employs 75 persons of whom 30 are based in Allschwil. The firm's strategy and business approach is based on five pillars that offer a sustainable development path for creating a successful company, which include Building a balanced portfolio. Evolva focuses on orally available small molecules in the belief that they are more convenient for patients and more cost-effective both from manufacture and administration points of view for the society, focus on differentiated pharmaceutical products with major benefits. Focusing on cardiovascular/renal and infectious diseases. Together they cause more than 50% of all deaths worldwide. Most of the top 20 pharmaceutical companies are active in both sectors, and all are active in one of the two sectors - hence widening Evolva's opportunities to partner. Building technology platform as the source of this differentiation. Evolva finds different structures with different properties from those found by the 99% of the industry that focuses on synthetic chemistry or proteins. Openness to unusual markets. The biotech business model has changed. As well as the established markets new opportunities arise in emerging countries such as India and China, and in adjacent sectors such as treatments against potential bio-terrorist and bio-warfare agents and the production of pharmaceutical and industrial chemical intermediates. Cost-effective implementation. Evolva places different functions around the globe according to where local conditions best suit. This approach both reduces Evolva's cost base and increases access to revenues, partners and talent. Evolva sees revenues and partners as important because they provide additional flexibility, resources and talent. Also, they provide important opportunities to better understand, and better meet, the needs of current and future customers. | Miscellaneous Commercial Services | Chief Tech/Sci/R&D Officer | |
NOVARTIS AG | Pharmaceuticals: Major | Corporate Officer/Principal | |
BASILEA PHARMACEUTICA AG | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
University of Basel | College/University | Corporate Officer/Principal | |
Eberhard Karls Universität Tübingen | College/University | Doctorate Degree | |
EVOLVA HOLDING SA | Food: Specialty/Candy | Director/Board Member | |
AntibioTx ApS
![]() AntibioTx ApS Pharmaceuticals: MajorHealth Technology AntibioTx ApS develops and manufactures pharmaceutical products. The private company is based in Kongens Lyngby, Denmark. | Pharmaceuticals: Major | Director/Board Member | |
UNION Therapeutics A/S
![]() UNION Therapeutics A/S Pharmaceuticals: MajorHealth Technology Union Therapeutics A/S operates as a clinical stage pharmaceutical company which focuses on the treatment of inflammatory skin disease. It also centers in the development of molecules exhibiting immunological and microbiological effects. The company is headquartered in Hellerup, Denmark. | Pharmaceuticals: Major | Director/Board Member | |
Synendos Therapeutics AG
![]() Synendos Therapeutics AG Medical SpecialtiesHealth Technology Synendos Therapeutics AG develops molecules for the treatment of anxiety and stress-related disorders. The company was founded by Andrea Chicca, Simon Russell and Jürg Gertsch in April 2019 and is headquartered in Allschwil, Switzerland. | Medical Specialties | Chairman |
Statistics
International
Denmark | 8 |
Switzerland | 8 |
Germany | 2 |
Sectoral
Health Technology | 8 |
Consumer Services | 5 |
Transportation | 2 |
Commercial Services | 2 |
Consumer Non-Durables | 2 |
Operational
Director/Board Member | 8 |
Corporate Officer/Principal | 5 |
Chief Executive Officer | 3 |
Doctorate Degree | 2 |
Chief Tech/Sci/R&D Officer | 2 |
Most connected contacts
- Stock Market
- Insiders
- Morten Kjærgaard Jakobsen
- Company connections